Emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or CNS depression.
Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to improve exercise capacity.
Treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
Maintenance therapy of acute lymphoblastic leukemia (ALL) as part of a combination regimen.
Multicentric Castleman’s disease (MCD) in adults who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Prevention and control of bleeding in hemophilia B.
Short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by a (+) skin test or in vitro testing for pollen-specific IgE antibodies.
Treatment of non-24-hour sleep-wake disorder (Non-24).